Genetesis, Inc., a Mason, Ohio-based cardiac imaging company, raised $9.2M in Series B financing.
This included strategic investments from TDK Ventures and an undisclosed Fortune 500 global healthcare company, as well as return investors CincyTech, Ohio Innovation Fund, and Mark Cuban.
The company has also added Sajid Malhotra to its Board of Directors.
Founded in 2013, Genetesis has developed the CardioFlux Magnetocardiograph (MCG) for chest pain, which causes eight million visits to hospital emergency departments annually. CardioFlux enables physicians to measure and record the magnetic fields of the heart in a few minutes, with the potential of lowering length of stay in the ER. It is done without the use of ionizing radiation, exercise or the need for specialized room modifications.